Lv1
35 积分 2021-02-19 加入
Intragenic ERBB2 kinase mutations in tumours
4个月前
已完结
Biomarkers for Antibody–Drug Conjugates in Solid Tumors
4个月前
已完结
GRADEing quality of evidence and its importance in evidence-based practice
6个月前
已完结
Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors
8个月前
已完结
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
11个月前
已完结
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
1年前
已完结
Interpretable HER2 scoring by evaluating clinical guidelines through a weakly supervised, constrained deep learning approach
1年前
已完结
Osimertinib in Resected EGFR-Mutated NSCLC
1年前
已完结
Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer
1年前
已完结
Antibody–drug conjugates come of age in oncology
1年前
已完结
皖公网安备34019202002308
